| 前收市價 | 44.21 |
| 開市 | 44.36 |
| 買盤 | 44.02 x 1200 |
| 賣出價 | 44.04 x 1200 |
| 今日波幅 | 43.33 - 44.42 |
| 52 週波幅 | 43.33 - 69.10 |
| 成交量 | |
| 平均成交量 | 15,909,093 |
| 市值 | 89.192B |
| Beta 值 (5 年，每月) | 0.39 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.10 |
| 業績公佈日 | 2024年7月26日 |
| 遠期股息及收益率 | 2.40 (5.43%) |
| 除息日 | 2024年4月04日 |
| 1 年預測目標價 | 52.57 |
Insider MonkeyBristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $-4.4, expectations were $-4.55. Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers […]
ZacksBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
- Reuters
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties. U.S. District Judge Zahid Quraishi in Trenton, New Jersey, became the fourth federal judge to uphold the program, one of Democratic President Joe Biden's signature initiatives, against drug industry challenges, rejecting their argument that it was an illegal taking of their property. "In short, defendants are not taking drugs from plaintiffs," Quraishi wrote, adding that they were free to stop participating in Medicare if they did not want to negotiate.
